Clinical trial · Observational
CYFIP1 and PKM2 Synergistically Regulate ROS and Glycolysis in Colorectal Cancer Through the AKT/mTOR/HIF-1α Cascad
NCT07197151CI-TRIAL-00095940completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Collect some tumor tissue specimens from patients who have undergone colorectal cancer surgery and conduct experiments such as immunohistochemistry to observe the expression of related genes in colorectal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer (CRC) | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Immunohistochemical determination of the expression levels of related genes
- timeFrame
- 2022.09-2025.09
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:(1) Patients diagnosed with colorectal cancer who received surgical treatment and postoperative chemotherapy (2) Patients who were conscious of their condition and voluntarily participated (3) No other serious underlying diseases Exclusion Criteria:(1) Concurrent other serious chronic diseases or organ damage (2) Diagnosed with benign colorectal tumors
References
Publications (0)
Data not yet available
No reference posted for this study.